Randomized response-adaptive designs in clinical trials
نویسندگان
چکیده
منابع مشابه
Response-Adaptive Repeated Measurement Designs for Clinical Trials
In a response-adaptive design (RAD), we review and update the trial on the basis of outcomes in order to achieve a specific goal. Optimal designs for clinical trials are usually constructed under a single objective. In this paper, we develop a new adaptive allocation rule to improve the current strategies of building response adaptive designs to construct multiple-objective designs. The purpose...
متن کاملBayesian response-adaptive designs for basket trials.
We develop a general class of response-adaptive Bayesian designs using hierarchical models, and provide open source software to implement them. Our work is motivated by recent master protocols in oncology, where several treatments are investigated simultaneously in one or multiple disease types, and treatment efficacy is expected to vary across biomarker-defined subpopulations. Adaptive trials ...
متن کاملBayesian Adaptive Designs for Clinical Trials
A Bayesian adaptive design is proposed for a comparative two-armed clinical trial using decision theoretical approaches. A loss function is specified to consider the cost for each patient, and the costs of making incorrect decisions at the end of a trial. At each interim analysis, the decision to terminate or to continue the trial is based on the expected loss function while concurrently incorp...
متن کاملAdaptive designs for confirmatory clinical trials.
Adaptive designs play an increasingly important role in clinical drug development. Such designs use accumulating data of an ongoing trial to decide how to modify design aspects without undermining the validity and integrity of the trial. Adaptive designs thus allow for a number of possible adaptations at midterm: Early stopping either for futility or success, sample size reassessment, change of...
متن کاملAdaptive enrichment designs for clinical trials.
Modern medicine has graduated from broad spectrum treatments to targeted therapeutics. New drugs recognize the recently discovered heterogeneity of many diseases previously considered to be fairly homogeneous. These treatments attack specific genetic pathways which are only dysregulated in some smaller subset of patients with the disease. Often this subset is only rudimentarily understood until...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biometrics
سال: 2015
ISSN: 0006-341X
DOI: 10.1111/biom.12289